GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations
- Registration Number
- NCT02082496
- Lead Sponsor
- University of Copenhagen
- Brief Summary
The obesity epidemic is attributable to dietary and behavioral trends acting on a person's genetic makeup to determine body mass and susceptibility to obesity-related diseases. Furthermore, common forms of obesity have a strong hereditary component and many genetic pathways that contribute to obesity have already ben identified.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that potentiates glucose-stimulated insulin secretion. However, GLP-1 also acts as an appetite-inhibiting hormone affecting the appetite center in the hypothalamus. Today, GLP-1 receptor agonists are available for the treatment of type 2 diabetes, and their treatment potential in obesity is an area of active research.
The aim of this study is to explore if the appetite inhibiting effect of GLP-1 is intact in people diagnosed with obesity causing genetic disorders and to investigate the physiological role of GLP-1 on food intake and appetite regulation in this group.
- Detailed Description
* Exploration of the physiological role of GLP-1 concerning food intake and appetite regulation in obese adults diagnosed with obesity related genetic disorders.
* Assessment of the effect of GLP-1 on body composition, bone mineral density, energy expenditure, cardiac function, glucose tolerance, insulin sensitivity, lipid concentrations and neuroendocrine function.
* Assessment of the impact of the leptin induced adaptive thermogenesis response in the weight reduced study participants.
* Investigating the alteration of the composition of gut bacteria as well as subjective ratings of satiety and hunger before after supplement with GLP-1.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- BMI above 28 (kg/m2)
- age 18-65 years
- otherwise healthy
- pregnancy or breastfeeding
- Type 2 Diabetes
- suffering from severe medical conditions
Recruitment for this study finished November 2015
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Case Group Liraglutide 4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection Control Group Liraglutide 4 months intervention with Liraglutide 3.0 mg daily as subcutanous injection
- Primary Outcome Measures
Name Time Method Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls 4 months intervention pmol/l
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Biomedical Sciences
🇩🇰Copenhagen, Denmark